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All living organisms have defense systems for combating
microorganisms and potential pathogens (Zasloff, 2002;
Dale et al., 2006; Martin et al., 2015). In the higher verte-
brates, prior to the evolution of adaptive immunity, a more
simpler and nonspeciﬁc system of innate immunity evolved
and still continues to play a role as the principal defense sys-
tem for almost all living organisms (Adonogianaki et al.,
1993, 1996; Aguilera et al., 1998). The innate immunity
modulates its antimicrobial functionality by small cationic
peptides with activity against gram-positive and negative bac-
teria, parasites, fungi and some viruses (Akalin et al., 1993;
Allaker et al., 1999; Allgrove et al., 2008). The mechanism
of action against microbes and pathogens is principally
attributed to the disruption of the microbial cell membrane
(van‘t Hof et al., 2001; Shai, 2002). However, complete
understanding of the exact process or processes is deﬁcient
and it is plausible that other mechanisms are at play which
are yet to be identiﬁed (Quinones-Mateu et al., 2003; Sinha
et al., 2003; Wang et al., 2004; Yasin et al., 2004; Gordon
et al., 2005a,b).
The innate immune system augments the physical and
chemical barriers e.g. skin and mucous membranes by produc-
ing antimicrobial peptides (AMPs) (Hancock and Sahl, 2006).
AMPs have a widespread distribution in human body and
have antimicrobial activity against microorganisms (Zasloff,
2002; Gordon et al., 2005a,b). All AMPs are extracted from
larger precursors and comprise of a signal sequence with
post-translational modiﬁcation that includes glycosylation
(Sewald and Jakubke, 2002), proteolysis (Vos et al., 1995),
amino-acids isomerization, carboxy-terminal amidation andTable 1 Representation of antimicrobial peptides classiﬁcation on
Classes
Anionic peptides
Linear cationic a-helical peptides
Cationic peptides enriched for speciﬁc amino acids
Anionic and cationic peptides (contain cysteine and disulﬁde bonds)
Anionic and cationic peptides fragments of larger proteinshalogenation (Bulet et al., 1993). To date around 106
Human host defense peptides have been identiﬁed (Wang,
2014). AMPs are found in oral saliva, in the epithelium and
in neutrophils (Dale et al., 2006). AMPs are classiﬁed in differ-
ent classes according to amino acid composition, size and con-
formational structures (Table 1) (Hancock and Lehrer, 1998;
Brogden, 2005; Harris et al., 2009).
The oral cavity has a very unique environment and
microorganisms and pathogens have easy access to it and the
rest of the body through epithelium and the gastrointestinal
tract (Dale and Fredericks, 2005). Despite the high microbial
load of the oral cavity that can potentially be disease forming,
abrasions, cuts and minor surgical procedures rarely lead to
infection. This indicates the highly effective host-defense
mechanisms that exist and are active (Zasloff, 2002). Oral
epithelial cells, salivary glands and neutrophils secrete at least
forty-ﬁve identiﬁable antimicrobial gene products that are
found in saliva. Saliva acts as a potent line of defense owing
to its antibacterial, antioxidant and antifungal properties
along with the oral mucosa, which plays a role as an important
barrier (Amerongen and Veerman, 2002; Yoshio et al., 2004).
The most common AMPs that express in the oral cavity are
listed in Table 2. Subsets of these AMPs are also expressed
in the crevicular ﬂuid and are more concentrated than in saliva
(Alves and Olivia Pereira, 2014; Ashby et al., 2014). In addi-
tion to their role played as antimicrobials, AMPs also serve
as effective biological molecules in immune activation, inﬂam-
mation and wound healing (Yang et al., 2002; Koczulla and
Bals, 2003; Yang et al., 2004) and are being extensively
researched upon for clinical applications (Koczulla and Bals,
2003; Dale et al., 2006; Meyer and Harder, 2007; Kang
et al., 2014; Vale et al., 2014).different basis.
Comments
They are small, rich in glutamic acids and aspartic acids,
present in human, cattle and sheep
They are short of cysteine and short peptides. e.g. LL37 from
human
They are proline rich peptides e.g. abaecin from honeybees
They contain cysteines with one or more disulﬁde bonds e.g.
protegrin from pigs, tachyplesins from horse crabs and a–b-
defensins from humans, cattle, mice and pigs
They are similar to other AMPs but their role in innate
immunity is not yet clear. e.g. lactoferricin from Lactoferrin
and casocidin-I from human casein
Table 2 Complete list of human oral antimicrobial peptides from Antimicrobial Peptide Database (APD).
Antimicrobial peptides Year Site of expression
a-Defensins (HNP-1) 1985 Neutrophils (azurophilic granules), gingival crevicular ﬂuid and bone marrow
a-Defensins (HNP-2) 1985 Neutrophils (azurophilic granules), gingival crevicular ﬂuid and bone marrow
a-Defensins (HNP-3) 1985 Neutrophils (azurophilic granules), gingival crevicular ﬂuid and bone marrow
a-Defensins (HNP-4) 1989 Neutrophils
b-Defensins (hBD-1) 1995 Suprabasal layer of stratiﬁed epithelium and saliva
b-Defensins (hBD-2) 1997 Gingival epithelium and saliva
b-Defensins (hBD-3) 2001 Skin and salivary gland
Histatin-1 1988 Saliva (parotid and submandibular)
Histatin-3 1988 Saliva (parotid and submandibular)
Histatin-5 1988 Saliva (parotid and submandibular)
Adrenomedullin 1993 Epithelium
Cathelicidins (LL-37) 1995 Neutrophils, inﬂamed epithelia, submandibular glands and saliva
http://aps.unmc.edu/AP/.
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Many studies have previously researched and reported the
mechanisms of action of AMPs against microorganisms
(Vos et al., 1995; Gennaro et al., 2002; Ganz, 2003;
Brogden, 2005; Dale et al., 2006; Gorr, 2009; Melo and
Castanho, 2012; Tomasinsig et al., 2012; Haney et al.,
2013; Wang, 2014). However, the mechanisms most widely
accepted are the barrel-stave model, carpet model, and toroi-
dal model for killing organisms. In barrel-stave model, pep-
tides position themselves for binding on the cell
membranes, this leads to peptide aggregation and conversion
to a bilayer membrane. So in this way the hydrophobic pep-
tides align with the lipid core and hydrophilic peptides form
an access pore in the interior part of membrane (Fig. 1a).
The carpet model is described as a disruption of the mem-
brane by the binding of peptides to the outer surface (phos-
pholipids) of cell membrane and forming a prolonged layer
or carpet (Fig. 1b). In the toroidal model, attached peptidesFigure 1 Illustration representing model of antimicrobial peptides fo
and (c) toroidal model.start aggregation and force the lipid monolayer to bend
incessantly through the pores. In this way the core is lined
by both the inserted peptides and the lipid head groups
(Fig. 1c) (Epand and Vogel, 1999; Bocchinfuso et al.,
2009). Types and role of antimicrobial peptides have been
discussed here.3. Types of oral antimicrobial peptides
3.1. Defensins
Defensins are short, cationic, low molecular weight (4–
5 kDa) peptides with 6–8 cysteine residues which form 3–4
intramolecular disulﬁde bonds (White et al., 1995). Defensins
are extensively studied due to their wide expression in human
body and the capability to kill all kind of gram-positive and
negative bacteria, fungi as well as viruses such as herpes
simplex (Ganz, 2003; Wang et al., 2004; Diamond and
Ryan, 2011; Wang, 2014). Human defensins are classiﬁed asr killing microorganisms. (a) Barrel-stave model, (b) carpet model
Figure 2 Molecular structure of human a-defensins with their cysteine consensus.
518 Z. Khurshid et al.a-, b- and h- on the basis of their length, location, position of
cysteine and folding of peptide chains (Abiko et al., 2007;
Greer et al., 2013).
Mature a-defensin family has been isolated from human
neutrophils such as hNP-1, hNP-2, hNP-3 and hNP-4
(Selsted et al., 1985). These neutrophils are nearly identical
in amino acid sequences but the N-terminus of hNP-1 ends
with alanine (Ala) and aspartate (Asp) for hNP-3 (Fig. 2).
These changes affect defensin antimicrobial spectrum as
already reported by Ganz et al. (1985). The hNP-3 is less active
than hNP-1 or hNP-3 in destroying Pseudomonas aeruginosa,
Staphylococcus aureus and Escherichia coli (Ganz et al.,
1985). hNP-4 has been researched and identiﬁed by Grifﬁth
et al. by chromatographic methods, as 33 amino acid
sequences expressed in neutrophils with activity against
E. coli, Streptococcus faecalis and Candida albicans (Wilde
et al., 1989). The last two family members of a-human neu-
trophils peptides (hNP-5 and hNP-6) are present in the enteric
system and do not express in the oral cavity (Gomes Pde and
Fernandes, 2010). In a healthy human, hNP-1 to 3 is most
abundantly present in saliva (around 99%). The levels of
hNP-4 are roughly 100 folds lower (Gabay et al., 1989;Figure 3 Molecular struGomes Pde and Fernandes, 2010). The concentration of
hNP-1 is higher in saliva of patients with oral diseases such
as lichen planus, leukoplakia and squamous cell carcinoma
in contrast to healthy individuals (Dunsche et al., 2001). The
level of hNP-1, -2 and -3 has been shown to be reduced in
edentulous patients due to the absence of gingival crevices
(Fanali et al., 2007). Dale et al. have reported low salivary
levels of a-defensins (hNP-1, -2 and -3) in patients having den-
tal caries and suggested that these are biological factors that
can be used for caries risk assessment in general population
(Dale et al., 2006).
The b-defensins family contains six members (hBD-1-6),
and principally they are all expressed in epithelial cells that
cover several tissues and organs including the skin, mucosal
surfaces of oral cavity, respiratory tract, gastrointestinal tract,
genitourinary tract, and kidney (Gorr, 2011). The molecular
structure of b-defensins is represented in Fig. 3. Research
has proved that only hBD-1, hBD-2, and hBD-3 are expressed
in the oral cavity (gingival epithelia, tongue, palate and buccal
mucosae, salivary glands/ducts and saliva) (Dale and
Krisanaprakornkit, 2001). Human Beta defensins-1 and -2
localized within the suprabasal layer of normal gingiva andctures of b-defensins.
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within the basal layer (Pisano et al., 2005). It has been sug-
gested that hBD-1 is continuously expressed and plays a role
in the impediment of normal ﬂora from becoming opportunis-
tic, whereas the hBD-2 and -3 are inducible in response to bac-
terial lipopolysaccharides (LPS), proinﬂammatory mediators
(Interleukins [IL-1b], tumor necrosis factors [TNF-a], interfer-
ons [IFN-c]) and are more effective against almost all patho-
gens (Krisanaprakornkit et al., 1998). These peptides are
in low concentration in the gingival crevicular ﬂuid.
Immunohistochemistry has been carried out in tissues sample
from radicular cyst, lichen planus, leukoplakia and candida
leukoplakia suggesting that hBD-2 is forcefully induced by
lichen-planus related inﬂammation and plays role in protecting
Candida albicans (Abiko et al., 2002). Zhao et al. reported that
the location of human genes for a-defensins and b-defensins is
adjacent to loci on chromosome 8p22-p23 (Liu et al., 1997).
3.2. Histatins
Histatins are a family of salivary proteins with low molecular
weight cationic peptides synthesized by the parotid and sub-
mandibular salivary ducts cells at around 50–425 lg/ml in
healthy adults (de Sousa-Pereira et al., 2013). They are 7–38
amino acid residues in length with at least 12 histidine residues,
hence called as histidine rich proteins. Histatins are predomi-
nantly antifungal and comprise of three main members (His-
1, His-3 and His-5) with other members being generated from
the proteolytic cleavage of these (Table 3) (MacKay et al.,
1984; Troxler et al., 1990). Along with the capability of inhibit-
ing the growth of Candida species, they have other functions
such as regulating oral hemostasis and bonding of metal ions
in saliva (Bercier et al., 1999; Oudhoff et al., 2009). Histatins
have high afﬁnity for enamel surfaces and play a role in the
formation of acquired enamel pellicle (Richardson et al.,
1993). Their antifungal mechanism has a few phases: bonding
to the speciﬁc membrane, transport through membrane, inhi-
bition of mitochondrial respiration by forming reactive oxygen
species, entering the cell by mobilization of ions (K+, Mg2+)
and causing cell death (Xu et al., 1991).
Oral candidiasis is a common infection in the human oral
cavity associated with trauma or in immunocompromised
patients due to low salivary ﬂow (Sjogren’s syndrome). In
these situations, histatins play an active positive role. In-vitro,Table 3 Histatin family with their proteolytic fragments.
Natural histatins present in saliva
Histatin 1
Histatin 3
Histatin 5
Proteolytic fragments in saliva
Histatin 2
Histatin 4
Histatin 6
Histatin 7
Histatin 8
Histatin 9
Histatin 10
Histatin 11
Histatin 12Hst-5 has been shown to inhibit Candida species (Candida albi-
cans, Candida glabrata, Candida krusei, and Cryptococcus neo-
formans) at physiological concentration (15–30 lM) (Raj et al.,
1990). Another study demonstrated that Hst M (middle por-
tion of Hst-3) has the same candida-cidal activity as the full
length molecule and this indicates the potential future use of
short length antifungal peptides for oral ointments (Raj
et al., 1990). Common cause of bioﬁlm in dental prosthesis is
by colonization of Candida and Hst-5 has showed potent limit-
ing effect on bioﬁlm in comparison with chlorhexidine
(Pusateri et al., 2009). A promising antimicrobial peptide
appears to be the histatin 5 12-mer P113 (Demegen) which
works as a mouth rinse for oral candidiasis in patients with
human immuno deﬁciency virus HIV (Gorr, 2009, 2011).
3.3. Cathelicidins (LL-37)
Cathelicidins (LL37) are AMPs from the family of a-helical
peptides without cysteine and located at the carboxyl terminus
of a 15–18 kDa highly conserved cathepsin-L-inhibitor (cathe-
lin)-like domain (Lehrer and Ganz, 2002; Kosciuczuk et al.,
2012). Cathelicidins only have one delegate in humans in the
oral cavity and respiratory tract which is known as human
cationic antimicrobial peptide (hCAP18) (Murakami et al.,
2002; Tecle et al., 2010). They are synthesized and stored in cells
as 2-domain proteins and when required are split by proteases
to produce a cathelin protein and an antimicrobial peptide.
They derive their name from the ﬁrst two residues at the N-ter-
minus (Leucine, Leucine) and contain 37 amino acids (Zanetti
et al., 2002). LL37/hCAP18 has the function of stimulation of
monocytes, neutrophils, mast cells and T-cells. Various studies
have demonstrated the capability of LL37/hCAP18 as a potent
antimicrobial against many gram-negative and positive bac-
teria, fungi, viruses and parasites (Tanaka et al., 2000; Isogai
et al., 2003b; Lo´pez-Garcı´a et al., 2005). LL37/hCAP18 neu-
tralizes bacteria very quickly by forming ionic channels in the
cell membranes of the microorganisms and by ability to bind
LPS of bacterial membranes (Zanetti et al., 2002). Turner,
Cho et al. reported minimal inhibitory concentration (MIC)
of LL37/hCAP18 range of less than 10 lg/ml against microor-
ganisms (Turner et al., 1998). Another study demonstrated the
stronger killing action of LL37/hCAP18 derived synthetic pep-
tides against Streptococcus sanguis (isolated from Behcet’s dis-
ease) (Isogai et al., 2003a). In addition, Ouhara et al. chemicallySequences
DSpHEKRHHGYRRKFHEKHHSHREFPFYGDYGSNYLYDN
DSHAKRHHGYKRKFHEKHHSHRGYRSNYLYDN
DSHAKRHHGYKRKFHEKHHSHRGY
RKFHEKHHSHREFPFYGDYGSNYLYDN
KFHEKHHSHRGYRSNYLYDN
DSHAKRHHGYKRKFHEKHHSHRGYR
RKFHEKHHSHRGY
KFHEKHHSHRGY
RKFHEKHHSHRGYR
KFHEKHHSHRGYR
KRHHGYKR
KRHHGYK
520 Z. Khurshid et al.synthesized human b-defensin-1 (hBD1), hBD2, hBD3 and
LL37 (CAP18) for their antimicrobial activity against oral bac-
teria (Streptococcus mutans, S. sanguinis, S. salivarius and S.
mitis) and demonstrated the high activity of LL37 against these
pathogens (Ouhara et al., 2005).
3.4. Adrenomedullin
Adrenomedullin is a cationic amphipathic peptide with one
disulﬁde bond. It is a proteolytically processed 185 amino acid
protein initially that is C-terminally amidated to create the
mature 52 amino acid adrenomedullin (Gorr, 2009). This
AMP is present in the gingival crevicular ﬂuid and saliva.
Although adrenomedullin is in both glandular and whole sal-
iva, it is in large concentrations in whole saliva (Gorr, 2009).
This suggests that the oral epithelial cells donate to the salivary
expression of adrenomedullin (Kapas et al., 2004). It has been
observed that the quantity of adrenomedullin is almost double
in periodontally compromised areas than in healthy areas
(Lundy et al., 2006).
3.5. Statherin
Statherin is a 5.4 kDa peptide belonging to the histatin/
statherin family. It is believed that statherin and a basic his-
tidine-rich peptide might have developed from a common
ancestral gene (Dickinson et al., 1987). Antimicrobial proper-
ties are observed in C-terminal peptide of the statherin
(Kochanska et al., 2000). Statherin is found in saliva
(Vitorino et al., 2004; Wilmarth et al., 2004; Denny et al.,
2008) and the gingival crevicular ﬂuid (Pisano et al., 2005).
This AMP is secreted by the submandibular and the parotid
glands and hinders the growth of anaerobic bacteria isolated
from the oral cavity (Vitorino et al., 2004; Wilmarth et al.,
2004; Denny et al., 2008). Statherin also restrains the crystal-
lization of calcium phosphate and hence may have a protective
role against plaque formation (Wilmarth et al., 2004; Denny
et al., 2008). The proteomic analysis of saliva acquired from
patients with high and low numbers for bacterial adhesion
and agglutination has revealed the potential of statherin to
be utilized as a biomarker for infections in oral cavity
(Rudney et al., 2009).
3.6. C–C motif chemokine 28
This is a 128-amino acid peptide, which is principally expressed
in a variety of epithelial cells, including salivary glands, and is
observed in saliva (Denny et al., 2008). The C–C motif chemo-
kine 28 acts both as a broad-spectral antimicrobial agent and
as a chemokine (Gorr, 2009). A C-terminal 28 amino peptide
has similarities with histatin 5 and this peptide is salt sensitive,
and increases the permeability of cell membrane, as has been
noted for other cationic AMPs (Hieshima et al., 2003).
3.7. Azurocidin
Human saliva proteomic analysis helped in the identiﬁcation
of azurocidin, which is a 37 kDa cationic antimicrobial protein
expressed in azurophil granules of neutrophils 1(264,55).
Azurocidin is a 251-amino acid protein which has strongantibacterial properties toward gram-negative bacteria due to
having strong afﬁnity for lipopolysaccharide (Gorr, 2009;
Dhaifalah et al., 2014). The two cysteine residues in positions
52 and 68 are thought to be essential for the antibacterial activ-
ity (Soehnlein and Lindbom, 2009).
3.8. Neuropeptides
Gingival crevicular ﬂuid contains the neuropeptides, calcitonin
gene related peptide and substance P (Awawdeh et al., 2002).
In addition to these peptides, the neuropeptide Y and vasoac-
tive intestinal peptide are also expressed and present in salivary
ﬂuids (Dawidson et al., 1997). However, their antimicrobial
role is extremely limited since their concentrations varying
from 2 to 45 pg/ml are lower by several orders of magnitude
than the minimum inhibitory concentrations required to be
effective against Candida albicans and bacteria (El Karim
et al., 2008).
3.9. Role of AMPs in oral diseases
The exposure of gingival epithelial cells with bacteria related to
periodontitis results in the production of b-defensins and LL-
37 (Gorr, 2009). Around twenty genetic disorders connected
with periodontal disease have been identiﬁed to date (Hart
and Atkinson, 2007). Some of these disorders are associated
with alterations in the AMP expression, which potentially
increases the susceptibility to bacterial infections (Gorr,
2009). It has been shown that conditions of sever congenital
neutropenia (Morbus Kostmann disease) are associated with
severe irreversible periodontitis (Putsep et al., 2002). These
patients have insufﬁcient LL-37 in neutrophils, saliva and
plasma. Also the a-defensins are markedly reduced (to about
30% of normal) while the lactoferrin content in plasma
remains normal (Putsep et al., 2002). Individuals suffering
from Morbus Kostmann when treated with granulocyte–col-
ony stimulating factor demonstrate regular neutrophil count
but still lack LL-37 and continue to suffer from advanced
periodontal disease (Carlsson et al., 1967; Putsep et al.,
2002). It has been observed that bone marrow transplantation
in a patient resulted in the restoration of both neutrophils and
LL-37 to normal levels. While this proved that LL-37 is related
to periodontal disease, normal levels were not enough to pre-
vent or restore the periodontal disease alone (Bachrach
et al., 2006; Gorr, 2009). Periodontal disease is also common
in children with Down’s Syndrome (Trisomy 21) (Orner,
1976). Mucin-7 and lactoferrin are other AMPs that are asso-
ciated with periodontal disease. In A. actinomycetemcomitans-
associated periodontitis, the levels of mucin-7 are decreased
three fold when compared with disease free patients
(Groenink et al., 1999). Lactoferrin levels are shown to be
within normal ranges, but the protein is iron saturated, indi-
cating a reduction in the antimicrobial properties in patients
with periodontitis (Groenink et al., 1999).
Other oral diseases and infections have also exhibited rela-
tions to the levels of expression of AMPs. Low levels of variety
of AMPs, including lactoferrin and b-defensins 1 and 2 are
associated with oral candidiasis (Tanida et al., 2003).
Remarkable variations in susceptibility to AMPs hBD3 and
LL-37 have been noted between different species of oral bac-
teria and different strains of the same species (Ji et al., 2007).
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is weakly susceptible to both AMP hBD3 and LL-37, while
Streptococcus. Gordonii 10,558 is highly susceptible. P. gingi-
valis 33,277, by contrast, is less susceptible to LL-37 but greatly
susceptible to death by hBD3 (Ji et al., 2007). Haim–Munk
syndrome and the Papillon–Lefe‘vre syndrome are induced
by allelic mutations of the cathepsin C gene, CTSC 1 and iden-
tiﬁed by severe periodontitis and palmoplantar keratoderma
(Hart, Hart et al., 2000). Although, patients with Papillon–
Lefe‘vre syndrome express normal levels of the cathelicidin pre-
cursor, very little is processed to the mature LL-37 peptide.
Similar to Morbus Kostmann, it is plausible that the decreased
levels of LL-37 result in occurrence of periodontitis in patients
with Papillon–Lefe‘vre syndrome (de Haar et al., 2006).
The interrelation of AMPs expression levels and occurrence
of caries have been difﬁcult to establish. Development of caries
in children has been linked with the low-level expression of a-
defensins (human neutrophil peptides 1–3) (Tao et al., 2005).
However, due to the fact that caries is observed at broad varia-
tion in a-defensin expression levels, it cannot be deﬁnitely
established whether a-defensin expression is accurately predic-
tive of development of future caries (Dale et al., 2006). Also,
salivary peroxidase and lactoferrin have not shown correlation
with occurrence of caries in clinical studies carried out in chil-
dren (Kirstila et al., 1998) and adults (Grahn et al., 1988). The
wide variety and range of AMP expression levels between
study subjects is possibly one of the strong reasons for the
complication in relating single point analysis of AMPs with
oral disease (Tenovuo et al., 1987). It is already known that
salivary peptide levels between patients can differ about 100-
fold (levels normalized to total salivary protein; Tao et al.,
2005). This makes it very challenging to express exact or nor-
mal values for individual AMPs. A multiplex investigative and
analytical approach toward antimicrobial protein expression
in healthy and diseased individuals with the aim to recognize
AMP signatures would potentially result in higher predictive/
diagnostic power.4. Conclusions
A wide range of AMPs with miscellaneous functions have been
discovered in the oral tissues and secretions. The protective
role played by these peptides against microbes entering the oral
cavity results in effective ﬁght against infections. The interest
in the potential use of AMPs as a therapeutic regimen is due
to their wide range of efﬁcacy and low rates of induced resis-
tance owing to the co-evolution of pathogens and the host
AMPs. After reviewing the literature we can conclude that
these AMPs have promising potential to be used against oral
microbes in order to control their growth and bioﬁlm forma-
tion. There are many challenges that need to be overcome in
order to design and synthesize AMPs that have the ability to
withstand the unique and harsh oral environment. AMPs are
expected in the future to be used as models for designing effec-
tive oral microbial antibiotics.References
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